YHB Investment Advisors Inc. Boosts Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

YHB Investment Advisors Inc. grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.1% in the 1st quarter, Holdings Channel reports. The institutional investor owned 43,570 shares of the medical research company’s stock after buying an additional 56 shares during the quarter. Amgen makes up 1.1% of YHB Investment Advisors Inc.’s holdings, making the stock its 19th biggest holding. YHB Investment Advisors Inc.’s holdings in Amgen were worth $13,574,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Pinney & Scofield Inc. purchased a new stake in shares of Amgen during the 4th quarter valued at $26,000. Ritter Daniher Financial Advisory LLC DE grew its stake in shares of Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock valued at $33,000 after buying an additional 51 shares during the period. Synergy Investment Management LLC purchased a new stake in shares of Amgen during the 4th quarter valued at $34,000. Atala Financial Inc purchased a new stake in shares of Amgen during the 4th quarter valued at $34,000. Finally, Heck Capital Advisors LLC purchased a new stake in shares of Amgen during the 4th quarter valued at $36,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on AMGN shares. Johnson Rice set a $294.00 price objective on shares of Amgen in a research note on Wednesday, March 5th. Wall Street Zen raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 18th. Mizuho upped their price target on shares of Amgen from $235.00 to $280.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 7th. Bank of America upped their price target on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research report on Wednesday, March 5th. Finally, Cantor Fitzgerald started coverage on shares of Amgen in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $305.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $309.22.

Insider Activity

In related news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the sale, the senior vice president now owns 8,162 shares in the company, valued at $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.69% of the company’s stock.

Amgen Stock Performance

Shares of Amgen stock opened at $272.44 on Tuesday. The firm has a market cap of $146.49 billion, a PE ratio of 24.86, a price-to-earnings-growth ratio of 2.62 and a beta of 0.51. The firm’s 50-day simple moving average is $281.39 and its 200-day simple moving average is $286.10. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.96 EPS. Equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.